1. Home
  2. KRP vs COLL Comparison

KRP vs COLL Comparison

Compare KRP & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kimbell Royalty Partners

KRP

Kimbell Royalty Partners

HOLD

Current Price

$15.18

Market Cap

1.4B

Sector

Energy

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$34.03

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRP
COLL
Founded
2013
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
2017
2015

Fundamental Metrics

Financial Performance
Metric
KRP
COLL
Price
$15.18
$34.03
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$17.33
$51.40
AVG Volume (30 Days)
949.4K
400.7K
Earning Date
05-07-2026
05-07-2026
Dividend Yield
10.25%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.40
Revenue
$333,830,000.00
$780,567,000.00
Revenue This Year
$6.88
$8.01
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$85.80
Revenue Growth
7.93
23.62
52 Week Low
$11.31
$28.74
52 Week High
$15.65
$50.79

Technical Indicators

Market Signals
Indicator
KRP
COLL
Relative Strength Index (RSI) 54.60 46.39
Support Level $14.10 $31.56
Resistance Level $15.65 $36.22
Average True Range (ATR) 0.32 1.67
MACD -0.01 -0.13
Stochastic Oscillator 71.84 11.85

Price Performance

Historical Comparison
KRP
COLL

About KRP Kimbell Royalty Partners

Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: